but not HS-5 conditioned media when cultured over a 48 hour time-course ( Figure 1C & D) . Furthermore, HS-5 conditioned media significantly diminished nilotinib-induced apoptosis as determined by annexin-V/7-AAD staining and flow cytometry, caspase 3/7 activity, and morphology (Supplementary Figures S1A-C). In agreement with the primary effect of conditioned media being on a reduction in apoptosis, conditioned media also showed no significant effect on cell cycle progression as analyzed by DAPI staining (Supplementary Figure S1D) .
To confirm that the effects of the drugs on apoptosis correlated with c-KIT inhibition, western blots for phospho-c-KIT and total c-KIT were performed on Kasumi-1 cells that had been treated with nilotinib for 4, 24, or 48 hours in either regular or HS-5 conditioned media ( Figure 1E ). Nilotinib treatment in regular media diminished c-KIT phosphorylation relative to total c-KIT protein levels at all time-points, consistent with a rapid and sustained c-KIT inhibition. In contrast, while nilotinib still inhibited phosphorylation of c-KIT in HS-5 conditioned media, the level of total c-KIT protein was also significantly diminished relative to regular media in the absence of nilotinib ( Figure 1E ). In agreement, the level of c-KIT cell surface expression, as assessed with an APC-conjugated c-KIT antibody and flow cytometry, was reduced in both the Kasumi-1 and SKNO-1 cell lines in HS-5 conditioned media ( Figure 1F ). The presence of stem cell factor (SCF), the ligand for c-KIT in HS-5 conditioned media, likely contributes to c-KIT down-regulation as c-KIT is rapidly internalized and degraded following ligand binding 6 ( Figure 1F ). However, in addition to the effects of HS-5 conditioned media on c-KIT protein stability, Kasumi-1 and SKNO-1 cells cultured in HS-5 conditioned media also exhibited significantly decreased c-KIT mRNA levels ( Figure 1G ). Together, these data suggest that the cause of c-KIT downregulation in HS-5 conditioned media is likely multi-factorial and occurs at both a transcriptional and post-translational level.
In an attempt to identify the soluble factor(s) mediating rescue of c-KIT inhibition we next examined a variety of cytokines secreted by HS-5 cells that are known to stimulate hematopoietic cells. We initially tested the effect of G-CSF, IL-6, and SCF on Kasumi-1 proliferation in the presence of c-KIT inhibitors. Figure 2A shows that G-CSF alone, but not IL-6 or SCF, could mimic the effects seen with HS-5 conditioned media. Furthermore, the concentration of G-CSF in the minimal amount of HS-5 conditioned media that affords rescue (240 pg/mL G-CSF) correlates well with the results of a G-CSF titration in the presence of nilotinib (EC50=140 pg/mL; Supplementary Figures S2A-C). Although this G-CSF concentration is greater than the average level of 25 pg/mL measured in healthy, normal adults 7 it is well below levels measured in patients immediately following myeloablative therapy (699 pg/mL) 8 or in patients with documented infections (731.8 pg/mL) 9 and thus may be clinically relevant. Further illustrating this dynamic regulation of cytokine production, we also found that treatment of the low cytokine secreting HS-27A human bone marrow stromal cell line with non-toxic doses of cytarabine and daunorubicin stimulated the release of sufficient G-CSF to partially rescue the effects of c-KIT inhibition on Kasumi-1 cells (Supplementary Figure S3C , D & E). Finally, a neutralizing antibody for the G-CSF receptor partially restored sensitivity of Kasumi-1 cells to c-KIT inhibitors in the presence of HS-5 conditioned media ( Figure 2B ). The lack of complete rescue may be due to incomplete neutralization of the receptor by the antibody or the ability of soluble factors other than G-CSF to provide partial rescue.
Having demonstrated a clear role for G-CSF in modulating the response of Kasumi-1 cells to c-KIT inhibition, we next examined the effect of G-CSF and other cytokines on the sensitivity of other c-KIT mutant leukemia cell lines to c-KIT inhibition. Surprisingly, SCF provided a more substantial rescue of the effects of c-KIT inhibition than G-CSF for the SKNO-1 cell line ( Figure 2C) . Similarly, for HMC1.1 10 , a mast cell leukemia cell line containing an activating c-KIT mutation, G-CSF did not rescue the effect of c-KIT inhibition, whereas IL-3 and GM-CSF both provided modest rescue ( Figure 2D ). To investigate whether the ability of G-CSF to rescue proliferation was correlated with receptor expression, the level of the G-CSF receptor expression on the leukemia cell surface was determined by flow cytometry. As seen in Figure 2E , over 80% of Kasumi-1 cells exhibited cell surface expression of the G-CSF receptor compared to <20% of SKNO-1 and HMC1.1 cells. In agreement, it has been previously shown that Kasumi-1 cells express significantly more G-CSF receptor mRNA than SKNO-1 cells 11 . These data suggest that the cell surface expression of the G-CSF receptor is correlated with the capacity of the cytokine to reverse sensitivity to c-KIT inhibition in Kasumi-1 cells and its failure to do so in SKNO-1 and HMC1.1 cells. Furthermore, the data suggest that directly targeting individual cytokines to restore c-KIT inhibitor sensitivity, as demonstrated in Figure 2B , may not be a viable therapeutic option unless the cytokine sensitivity is profiled for each c-KIT dependent leukemia.
These results also have additional implications for understanding leukemia development, maintenance, and therapy. In fitting with the two-step model of AML development 12 , it is hypothesized that the t(8;21) (AML1/ETO) or inv(16) translocation impairs hematopoietic differentiation and cooperates with an activating c-KIT mutation to confer a proliferative advantage and full leukemic transformation 13 . Murine models have elegantly supported this model as activating c-KIT mutations cooperate with the full length AML1/ETO translocation to induce leukemia in the mouse 14 . However, the requirements for leukemia maintenance may be different than those required for leukemia development. Consistent with this, when c-KIT mutant leukemia cell lines are cultured with stromal conditioned media, c-KIT signaling appears to be dispensable for leukemia cell maintenance as i) the c-KIT leukemia cell lines are relatively resistant to c-KIT inhibitors in stromal conditioned media despite adequate c-KIT inhibition as seen by western blot (Figure 1E) , and ii) c-KIT dependent leukemia cells proliferate in stromal conditioned media despite extensive downregulation of c-KIT ( Figure 1E, F, & G) . These data suggest that mutant c-KIT signaling may not be required for leukemia maintenance in the presence of leukemia stem cell nichederived pro-survival cytokines. This has implications for both understanding leukemia development and raises concerns about the efficacy of targeting mutant c-KIT in AML, although when combined with conventional cytotoxic therapy there may be an additive or synergistic effect that would render it a more effective therapeutic strategy. The proliferation of Kasumi-1 leukemia cells was assessed with the CellTiter-Glo viability assay following treatment with the specified c-KIT inhibitor (1 μM) for 48 hours in regular media supplemented with 10 ng/mL G-CSF, SCF, or IL-6. *=p<0.05 (imatinib) and **=p<0.01 (nilotinib) when comparing regular and G-CSF supplemented media. (B) The proliferation of Kasumi-1 cells was assessed with the CellTiter-Glo viability assay following treatment with the specified c-KIT inhibitor (1 μM) for 48 hours in either regular media, regular media supplemented with a G-CSF receptor neutralizing antibody (1 μg/mL; R&D Systems), 0.05% HS-5 conditioned media, or 0.05% HS-5 conditioned media supplemented with a G-CSF receptor neutralizing antibody. The data are normalized to the untreated controls and are the mean +/− SEM from three independent experiments. For both imatinib and nilotinib p ≥ 0.001 when comparing HS-5 conditioned media against all other conditions. The SKNO-1 (C) and HMC1.1 (D) c-KIT dependent leukemia cells lines were treated with a c-KIT inhibitor (1 μM for SKNO-1 and 200 nM for HMC1.1) for 48 hours in regular media supplemented with 10 ng/mL G-CSF, SCF, GM-CSF, or IL-3 and assessed with the CellTiter-Glo viability assay. The data are normalized to the untreated controls and are the mean +/− SEM from three independent experiments. In (C), *=p ≥ 0.001 (imatinib) and **=p<0.05 (nilotinib) when comparing regular media and SCF supplemented media. In (D), *=p ≥ 0.0001 for both imatinib and nilotinib when comparing regular and HS-5 conditioned media. (E) Kasumi-1, SKNO-1, and HMC1.1 cells were stained with a PE conjugated anti-G-CSF receptor antibody (Biolegend) and assessed by flow cytometry. The data are the mean +/− SEM from three independent experiments.
